Off-the-Shelf cell therapy tested in patients with Tough-to-Treat blood cancers
NCT ID NCT06325748
Summary
This early-stage study is testing a new, ready-made cell therapy called SENTI-202 in adults with advanced blood cancers that have returned or not responded to prior treatments. The main goals are to find a safe dose and see if the therapy shows any early signs of fighting the cancer. The therapy involves giving patients modified immune cells designed to target specific markers found on their cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML/MDS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Methodist Healthcare
San Antonio, Texas, 78229, United States
-
Peter MacCallum Cancer Center
Melbourne, Victoria, 3000, Australia
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
TriStar Bone Marrow Transplant
Nashville, Tennessee, 37203, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.